<a href="https://laohu8.com/S/STTK">Shattuck Labs</a> reports third quarter 2025 financial results
Shattuck Labs Inc. reported a net loss of $10.1 million, or $0.14 per basic and diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $16.6 million, or $0.33 per basic and diluted share, for the same period in 2024. Research and development expenses were $7.6 million, down from $16.3 million in the prior year quarter. General and administrative expenses were $4.1 million, compared to $4.6 million in the third quarter of 2024. As of September 30, 2025, cash and cash equivalents and short-term investments totaled $86.1 million, compared to $90.1 million as of September 30, 2024. The company closed a private placement of up to $103 million in August 2025 and dosed the first participants in a Phase 1 clinical trial of SL-325. Dan Baker, M.D., and Mona Ashiya, Ph.D., were appointed to the Board of Directors. Shattuck Labs expects current cash resources, assuming full exercise of outstanding common stock warrants, to fund operations into 2029.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570628-en) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.